About Cyxone

Cyxone develops new innovative therapies for the treatment of rheumatoid arthritis and multiple sclerosis. Our goal is to improve the quality of life for patients in need of a more effective, convenient and safe treatment option.

Our Drug Projects

Rheumatoid Arthritis (rabeximod)

A unique mechanism-of-action combined with a convenient oral administration and a beneficial tolerability profile

Multiple sclerosis (T20K)

Acts to stop or slow down the progression of multiple sclerosis

Our mission is to provide better therapies for patients suffering from autoimmune diseases

Press Releases

Kjell Stenberg new CEO in Cyxone AB

April 22, 2024 10:02 (CEST)

Regulatory
Cyxone enters important research collaboration

March 25, 2024 13:44 (CET)
Cyxone reaches important milestone regarding mechanism of action

January 15, 2024 10:01 (CET)

About Cyxone

Our Drug Projects

Rheumatoid Arthritis (rabeximod)

Multiple sclerosis (T20K)

Press Releases

Kjell Stenberg new CEO in Cyxone AB

Cyxone enters important research collaboration

Cyxone reaches important milestone regarding mechanism of action

Subscribe to Press Releases